Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.

David A Bushinsky, Jeffrey J Budden,Philip A Kalra,Jinwei Yuan,Carol Moreno Quinn,Murray Epstein

American journal of kidney diseases : the official journal of the National Kidney Foundation（2023）

引用 2|浏览6

暂无评分

摘要

Reductions in sP and sK to the normal range were observed following 2 weeks of patiromer treatment and sustained during 4 weeks treatment among patients with non-dialysis dependent CKD, hyperkalemia, and hyperphosphatemia. Future controlled trials are needed to establish if patiromer is useful to reduce both sK and sP in hyperkalemic patients with CKD and hyperphosphatemia.

查看译文

关键词

Index (key) words: Hyperphosphatemia,chronic kidney disease,hyperkalemia,patiromer,potassium binder

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要